5J74

Fluorogen activating protein AM2.2 in complex with TO1-2p

  • Classification: IMMUNE SYSTEM
  • Expression System: Pichia

  • Deposited: 2016-04-05 Released: 2016-05-25 
  • Deposition Author(s): Stanfield, R.L., Wilson, I.A., Wu, Y.
  • Funding Organization(s): National Institutes of Health/National Institute of Mental Health; National Institutes of Health/National Center for Research Resources 

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.7 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.197 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair.

Wu, Y.Stauffer, S.R.Stanfield, R.L.Tapia, P.H.Ursu, O.Fisher, G.W.Szent-Gyorgyi, C.Evangelisti, A.Waller, A.Strouse, J.J.Carter, M.B.Bologa, C.Gouveia, K.Poslusney, M.Waggoner, A.S.Lindsley, C.W.Jarvik, J.W.Sklar, L.A.

(2016) J Biomol Screen 21: 74-87

  • DOI: 10.1177/1087057115609145
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • A new class of biosensors, fluorogen activating proteins (FAPs), has been successfully used to track receptor trafficking in live cells. Unlike the traditional fluorescent proteins (FPs), FAPs do not fluoresce unless bound to their specific small-mol ...

    A new class of biosensors, fluorogen activating proteins (FAPs), has been successfully used to track receptor trafficking in live cells. Unlike the traditional fluorescent proteins (FPs), FAPs do not fluoresce unless bound to their specific small-molecule fluorogens, and thus FAP-based assays are highly sensitive. Application of the FAP-based assay for protein trafficking in high-throughput flow cytometry resulted in the discovery of a new class of compounds that interferes with the binding between fluorogens and FAP, thus blocking the fluorescence signal. These compounds are high-affinity, nonfluorescent analogs of fluorogens with little or no toxicity to the tested cells and no apparent interference with the normal function of FAP-tagged receptors. The most potent compound among these, N,4-dimethyl-N-(2-oxo-2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)benzenesulfonamide (ML342), has been investigated in detail. X-ray crystallographic analysis revealed that ML342 competes with the fluorogen, sulfonated thiazole orange coupled to diethylene glycol diamine (TO1-2p), for the same binding site on a FAP, AM2.2. Kinetic analysis shows that the FAP-fluorogen interaction is more complex than a homogeneous one-site binding process, with multiple conformational states of the fluorogen and/or the FAP, and possible dimerization of the FAP moiety involved in the process.


    Organizational Affiliation

    Department of Pathology, University of New Mexico, Albuquerque, NM, USA Center for Molecular Discovery, University of New Mexico, Albuquerque, NM, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
scFv AM2.2
A, B
264N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
PO4
Query on PO4

Download SDF File 
Download CCD File 
A, B
PHOSPHATE ION
O4 P
NBIIXXVUZAFLBC-UHFFFAOYSA-K
 Ligand Interaction
6GN
Query on 6GN

Download SDF File 
Download CCD File 
A, B
1-(17-amino-5,8-dioxo-12,15-dioxa-4,9-diazaheptadecan-1-yl)-4-{[3-(3-sulfopropyl)-1,3-benzothiazol-3-ium-2-yl]methyl}quinolin-1-ium
C33 H45 N5 O7 S2
WTDQEZATLRLHFH-UHFFFAOYSA-P
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.7 Å
  • R-Value Free: 0.250 
  • R-Value Work: 0.197 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 79.448α = 90.00
b = 114.830β = 90.00
c = 130.995γ = 90.00
Software Package:
Software NamePurpose
SCALEPACKdata scaling
PHASERphasing
REFMACrefinement
DENZOdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of Mental HealthUnited States1U54MH084690-02
National Institutes of Health/National Institute of Mental HealthUnited States5U54MH084690-03 CDP2
National Institutes of Health/National Institute of Mental HealthUnited StatesU54MH084659
National Institutes of Health/National Center for Research ResourcesUnited States5U54RR022241

Revision History 

  • Version 1.0: 2016-05-25
    Type: Initial release
  • Version 1.1: 2017-09-13
    Type: Author supporting evidence, Derived calculations